DrugPatentWatch Database Preview
Cipla Company Profile
What is the competitive landscape for CIPLA, and when can generic versions of CIPLA drugs launch?
CIPLA has eighty-seven approved drugs.
There are four US patents protecting CIPLA drugs. There are thirty-two tentative approvals on CIPLA drugs.
There are twenty-three patent family members on CIPLA drugs in twenty-one countries and three hundred supplementary protection certificates in fifteen countries.
Summary for Cipla
| International Patents: | 23 |
| US Patents: | 4 |
| Tradenames: | 77 |
| Ingredients: | 77 |
| NDAs: | 87 |
| Patent Litigation for Cipla: | See patent lawsuits for Cipla |
| PTAB Cases with Cipla as petitioner: | See PTAB cases with Cipla as petitioner |
Drugs and US Patents for Cipla
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cipla | FAMCICLOVIR | famciclovir | TABLET;ORAL | 078278-003 | Mar 21, 2011 | AB | RX | No | No | See Pricing | See Pricing | ||||
| Cipla | GEMCITABINE HYDROCHLORIDE | gemcitabine hydrochloride | INJECTABLE;INJECTION | 078759-002 | Jul 25, 2011 | AP | RX | No | No | See Pricing | See Pricing | ||||
| Cipla | DARIFENACIN HYDROBROMIDE | darifenacin hydrobromide | TABLET, EXTENDED RELEASE;ORAL | 207664-001 | Sep 1, 2016 | AB | RX | No | No | See Pricing | See Pricing | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for Cipla Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| South Korea | 20100110297 | See Pricing |
| Brazil | PI0819319 | See Pricing |
| Eurasian Patent Organization | 201070597 | See Pricing |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Cipla Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1632232 | PA2016043 | Lithuania | See Pricing | PRODUCT NAME: RILPIVIRINO HIDROCHLORIDAS + TENOFOVIRO ALAFENAMIDAS; REGISTRATION NO/DATE: EU/1/16/1112 20160621 |
| 1419152 | 2012C/022 | Belgium | See Pricing | PRODUCT NAME: EMTRICITABINE/RILPIVIRINE/TENOFOVIR DISOPROXIL; AUTHORISATION NUMBER AND DATE: EU/1/11/737/001 20111128 |
| 0582455 | SPC/GB00/035 | United Kingdom | See Pricing | PRODUCT NAME: EFAVIRENZ, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT; REGISTERED: CH IKS-54 908 01 19981120; CH IKS-54 908 02 19981120; CH IKS-54 908 03 19981120; UK EU/1/99/110/001 19990528; UK EU/1/99/110/002 19990528; UK EU/1/99/110/003 19990528; UK EU/1/99/110/004 19990528; UK EU/1/99/111/001 19990528; UK EU/1/99/111/002 19990528; UK EU/1/99/111/003 19990528; UK EU/1/99/111/004 19990528 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
